JAK2 and acquired polycythemia vera: The 2016 WHO classification system for hematopoietic tumors recognizes the almost perfect association between PV and a JAK2 mutation, as well as the fact that JAK2V617F is also detected in 50–70% of patients with either ET or PMF [45].